Short answer
PepGen Inc (PEPG) filed an 8-K current report with the SEC on March 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Q4 and full-year 2025 results announced March 4, 2026; financials in Exhibit 99.1 press release.
PepGen Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 results announced March 4, 2026; financials in Exhibit 99.1 press release
- Filing furnished (not filed), limiting legal liability under Exchange Act Section 18
- Investors should reference Exhibit 99.1 for all financial figures and corporate highlights
Item 8.01 · Other Events
- FDA issued partial clinical hold on FREEDOM2-DM1 Phase 2 MAD trial of PGN-EDODM1 in myotonic dystrophy type 1 (DM1) patients
- Partial hold (vs. full) suggests FDA concern is likely protocol-specific: trial cannot proceed until FDA requirements are resolved
- DM1 program appears to be a key pipeline asset; hold materially delays clinical timeline and raises regulatory risk for PEPG
- Investor watch: resolution timeline and nature of FDA's concern (safety vs. trial design) will be critical to share price recovery
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PepGen Inc 8-K filings
Get the next PEPG 8-K as it lands
Follow PEPG for push alerts, or ask the research agent what this filing means.